R. Barnabas, E. Brown, A. Bershteyn, H. S. Stankiewicz Karita, C. Johnston, L. Thorpe, A. Kottkamp, K. Neuzil, M. Laufer, M. Deming, M. Paasche-Orlow, P. Kissinger, A. Luk, K. Paolino, R. Landovitz, Risa M. Hoffman, T. Schaafsma, M. Krows, K. Thomas, Susan Morrison, Harald S. Haugen, L. Kidoguchi, M. Wener, A. Greninger, Meei-Li W Huang, K. Jerome, A. Wald, C. Celum, H. Chu, J. Baeten
Annals of Internal Medicine, 2020
Clinical trials have ruled out a role of hydroxychloroquine in the treatment of COVID-19, but it has been hypothesized that hydroxychloroquine's activity against SARS-CoV-2 in the laboratory suggests a role in prevention. This randomized controlled trial tests hydroxychloroquine as postexposure prophylaxis for SARS-CoV-2 infection.
Cited by 25 publications.
Field of study: Medicine